ストックスクリーナーアプリを入手
5.14
0.59%
0.03
アフターアワーズ：
4.99
-0.15
-2.92%
Lexeo Therapeutics Inc (LXEO) 最新ニュース
Lexeo Therapeutics (LXEO) Slips 2.29% as Stock Tests Key Support LevelsBPI Bear Correction - Newser
Lexeo Therapeutics Q1 2026 Earnings: EPS Beat on Lower Operating CostsProfit Announcement - Newser
LXEO Stock Chart | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Lexeo Therapeutics (LXEO) Sees Mild Gains as Stock Holds Above Key SupportMomentum Trade - Newser
Top Executive Makes Notable Move in Lexeo Therapeutics Stock - TipRanks
Lexeo (LXEO) COO sells 1,302 shares in tax-related stock sale - Stock Titan
Lexeo Therapeutics (LXEO) CEO sells 3,342 shares in tax-related RSU transaction - Stock Titan
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - Caledonian Record
LXEO (NASDAQ:LXEO) Rule 144 notice: 3,342 vested shares; prior sale 10,173 - Stock Titan
LXEO (NASDAQ: LXEO) lists restricted stock vesting; Form 144 shows past sale - Stock Titan
LXEO (NASDAQ: LXEO) insider sale notice — 1,595 vested shares - Stock Titan
Paradigm BioCapital holds 6.18M Lexeo shares (LXEO); 8.3% stake reported - Stock Titan
Balyasny groups disclose 7.18M shares in Lexeo Therapeutics (LXEO) - Stock Titan
Lexeo Therapeutics, Inc. (LXEO) Eps Diluted (TTM) - Zacks Investment Research
Lexeo Therapeutics Price Target Maintained With a $17.00/Share by Chardan Capital - Moomoo
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Lexeo Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Stifel Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Chardan Capital Reaffirms "Buy" Rating for Lexeo Therapeutics (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics, Inc. Q1 2026 10-Q Report: Financial Results, Forward-Looking Statements, and Key Disclosures - Minichart
Why Lexeo Therapeutics (LXEO) looks attractive at current levels (Parabolic) 2026-05-11Community Sell Signals - newser.com
Lexeo Therapeutics Reports Q1 2026 Results, Advances Cardiac Gene Therapy Pipeline, and Awaits FDA Feedback on Pivotal Trial - Minichart
Raymond James reiterates Strong Buy on Lexeo stock, $25 target By Investing.com - Investing.com Canada
Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lexeo Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Lexeo Highlights Q1 Progress Advancing Cardiac Gene Therapies - TipRanks
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights - The Manila Times
EDGAR Filing Documents for 0001193125-26-215674 - SEC.gov
Lexeo Therapeutics, Inc. 1Q 2026: Net income $(20.2M), EPS $(0.25) — 10-Q Summary - TradingView
Lexeo Therapeutics (NASDAQ: LXEO) posts lower Q1 loss with $227.6M cash - Stock Titan
Lexeo (Nasdaq: LXEO) trims Q1 loss and advances pivotal cardiac gene therapy plans - Stock Titan
Lexeo readies Friedreich ataxia pivotal trial, cash runway into 2028 - Stock Titan
Lexeo Therapeutics (LXEO) Price Target Increased by 19.77% to 21.29 - MSN
Lexeo Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
LXEO: Lexeo Therapeutics, Inc.Interactive Chart - Zacks Investment Research
The scenario planning at Lexeo Therapeutics (LXEO) | Q4 2025: EPS Beats ForecastsCommunity Buy Alerts - Newser
Why Lexeo Therapeutics (LXEO) ability to generate cash matters (Smart Money Active) 2026-05-06Turnaround Stocks - newser.com
Lexeo Therapeutics (LXEO) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Lexeo Therapeutics Adds Genomic Medicine Leader to Board - TipRanks
Lexeo Therapeutics (LXEO) director receives 50,000 stock options at $5.81 strike - Stock Titan
Lexeo Therapeutics (LXEO) director Laura Sepp-Lorenzino files Form 3 - Stock Titan
[ARS] Lexeo Therapeutics, Inc. SEC Filing - Stock Titan
Lexeo Therapeutics (NASDAQ: LXEO) details 2026 virtual meeting, board elections and pay - Stock Titan
Dr. Laura Sepp-Lorenzino joins Lexeo Therapeutics (LXEO) board and science committee - Stock Titan
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - The Manila Times
Lexeo Therapeutics to Present New Cardiac Gene Therapy Data at ASGCT Annual Meeting 2026 - Quiver Quantitative
Lexeo brings Friedreich ataxia, heart gene therapy data to Boston - Stock Titan
We Think Lexeo Therapeutics (NASDAQ:LXEO) Needs To Drive Business Growth Carefully - Moomoo
LXEO SEC FilingsLexeo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is Lexeo Therapeutics (LXEO) stock a good candidate for accumulation (Volatility Increases) 2026-04-20Social Buy Zones - UBND thành phố Hải Phòng
Suvretta Capital Management, LLC Increases Stake in Lexeo Therap - GuruFocus
Suvretta, Averill disclose multi-million share holdings in Lexeo Therapeutics (NASDAQ: LXEO) - Stock Titan
What do insiders think about Lexeo Therapeutics (LXEO) Stock | Price at $6.14, Up 2.68%Late Breakout - Newser
What chart pattern is Lexeo Therapeutics (LXEO) Stock forming | Price at $6.20, Down 3.58%Upside Potential - Newser
Layoff Watch: Is Lexeo Therapeutics Inc backed by strong institutional buying2026 Big Picture & Expert Curated Trade Setup Alerts - baoquankhu1.vn
CEO Change: Is Lexeo Therapeutics Inc attractive for institutional investors2026 Intraday Action & Accurate Intraday Trade Tips - baoquankhu1.vn
Insiders In Lexeo Therapeutics Left Out From 14% Price Rise After Disposing Stock - simplywall.st
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):